(PRESS RELEASE) PARIS, 29-Mar-2022 — /EuropaWire/ — Sanofi (EPA: SAN), a global biopharmaceutical company focused on human health, has announced…
(PRESS RELEASE) CAMBRIDGE, 5-Jan-2021 — /EuropaWire/ — AstraZeneca (LON: AZN), a British-Swedish multinational pharmaceutical and biotechnology company, has announced the…
Agreement sharpens AstraZeneca’s focus on priority medicines in Respiratory & Immunology portfolio (PRESS RELEASE) CAMBRIDGE, 1-Nov-2021 — /EuropaWire/ — AstraZeneca…
A thousand people are needed for ground-breaking research being carried out by the University of Birmingham into an incurable lung…
LONDON, 20-Apr-2018 — /EuropaWire/ — Once-daily single inhaler triple therapy superior to Relvar/Breo Ellipta and Anoro Ellipta across multiple endpoints…
https://youtu.be/T-9OK8yHfmQ Philips joins COPD Foundation and family of late Leonard Nimoy in asking the world to #BreatheBoldly on social media…
Your Time campaign calls for earlier action in COPD WHO expects COPD to be the third leading cause of death…
QVA149 improved lung function, breathlessness and health-related quality of life in moderate-to-severe COPD patients, according to EXPEDITION trial results[1]-[7] GEM…
Results are among key AstraZeneca respiratory data being presented at 2014 European Respiratory Society International Congress LONDON, 8-9-2014 — /EuropaWire/…
London, 29-4-2014 — /EuropaWire/ — GlaxoSmithKline plc (LSE/NYSE: GSK) announced today that the European Commission has granted marketing authorisation for Incruse® (umeclidinium) as…
Most of the 64 million COPD patients around the world, including over 2 million in Spain, must contend with breathlessness,…
21-5-2013 — /europawire.eu/ — Men experience a higher burden of disease and lower life expectancy than women, but policies focusing on…